OC
NVAX icon

Oarsman Capital’s Novavax NVAX Stock Holding History

Oarsman Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$63 – 930
2024
Q3 		$63 Buy
+5
New +$65 ﹤0.01% 902

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Oarsman Capital's NVAX Position: Q4 2024 in Review

Oarsman Capital sold out of Novavax (NVAX) in Q4 2024, closing a stake of 5 shares — an estimated $63 sold.

Oarsman Capital first reported a position in NVAX in Q3 2024 and held it in 1 quarter. The position peaked at $63 in Q3 2024. 234 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

  • Oarsman Capital reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
  • Oarsman Capital sold 5 Novavax shares in Q4 2024, an estimated $63.
  • Oarsman Capital first reported a position in Novavax in Q3 2024 and held it in 1 quarter.
  • Oarsman Capital's Novavax position peaked at $63 in Q3 2024.
  • 234 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on Oarsman Capital's 13F filing for Q4 2024, filed 13 Feb 2025.